With "Green Patents", BPTO accelerates approval of "sustainable inventions"

With “Green Patents”, BPTO accelerates approval of “sustainable inventions”

A special program of the BPTO can speed up the decision-making process for granting patents for projects that support a sustainable economy. Green Patents speeds up the process for projects aimed at technologies that promote a lower environmental impact.

Between January 2020 and March 2021 there were 118 applications for priority exam based on the program. Of these, 32 requests have already been decided, with a 65% concession and an average time between the request for an accelerated examination and the end of the process of just eight months.

“In order to be eligible for the accelerated procedure, the patent application must include inventions related to technologies for alternative energy generation, biofuels; for transportation, such as hybrid or electric vehicles; for energy conservation; and for waste management or sustainable agriculture, such as fertilizers, irrigation techniques, among others”, says Ana Cristina Müller, an expert on the subject.

In addition to the “Green Patents”, the specialist says that there are other ways to speed up the exam. An example are cases of infringement of the object of a patent application, that is, when there is a third-party product or process on the market that is reproducing, without authorization from the applicant, an invention that already has a patent application in progress.

“For these, the applicant can request the expediting of the examination, simply sending an extrajudicial notification to the potential offender as evidence that the offense is taking place.”

Source: Exame


NASA Patents New Faster, Cheaper Route to the Moon

A record published by the US Patent and Trademark Office recently called attention even though it did not reveal equipment or technology. It is a new trajectory for the Moon, developed by NASA engineers. The unprecedented route for travel to the natural satellite saves money, time and fuel, as well as providing unprecedented discoveries about the Universe for the first mission to explore it.

Through this technique, smaller spacecraft can hitch a ride on missions launched to Geosynchronous Earth Orbit, a region that is the destination of many satellites. There, they would be able to perform a series of maneuvers at any time of the year and without restrictions on time and inclination to enter lunar orbit, making a faster trip and with little or no fuel.

Due to its characteristics, it is aimed at spaceships of reduced size and low budget, so larger missions, with spacecraft carrying astronauts and rovers, cannot benefit from this route.

DAPPER Mission

One of the first missions to use the new path to the Moon will be the Dark Ages Polarimeter Pathfinder (DAPPER), a project created by astrophysicists at the University of Colorado (USA). The same size as a microwave, the spacecraft is compact enough to travel as a secondary payload in a larger spacecraft to geosynchronous orbit and from there begin its journey to the Moon using only “a modest fuel tank” for adjustments. steering.

Still with no scheduled launch date, DAPPER will pick up low-frequency radio signals from the dark side of the Moon, from 13 billion years ago, avoiding interference caused by Earth’s electronic devices. By escaping these blockages, the equipment can find evidence of the first stars, black holes and galaxies formed about 500 million years after the Big Bang.

Source: Tecmundo

Butantan registra patente de vacina contra E. coli

Butantan registers patent for vaccine against E. coli

After receiving patent approval for a vaccine against the enteropathogenic Escherichia coli bacteria, the Butantan Institute is working on the development of an immunizing agent against the disease, capable of causing diarrhea that leads to death. Also known by the acronym EPEC, an enteropathogenic Escherichia coli is one of the six pathogenic categories of E. coli that cause intestinal disease. Transmitted via the fecal-oral route, that is, through the ingestion of contaminated water or food, it is common in developing countries due to the lack of basic sanitation, and annually kills up to 2 million children worldwide from diarrhea.

The issue sensitized Wilmar Dias da Silva’s professor and researcher at Butantan in 2005, during the Thematic Cooperation Program in the Matter of Science and Technology (Proáfrica), a technology transfer project for the creation of a serpentarium in Mozambique. Back in Brazil, he devised a recombinant vaccine to fight the disease. In this type of immunizing agent, which is obtained through genetic engineering, there is a combination of DNA or RNA from different organisms, the result of which is inserted into a vector – in this case, the chosen one was the BCG bacterium, which is widely used in research for its safety and immunogenic properties.

Who accepted the challenge of taking the project forward, under the supervision of Wilmar and researcher Roxane Piazza, from the Bacteriology Laboratory, among other scientists from the Butantan, was the then master’s student at the University of São Paulo (USP) Halyka Vasconcellos. “We inserted the genes of two proteins, BFPA, and intimin, which are responsible for the adhesion of EPEC in the intestine, inside the BCG. We then applied this modified BCG in mice, generating a positive immune response”, summarizes the researcher. The work was published in the renowned journal Vaccine, in 2012, but continued to be improved by Halyka throughout her doctorate and postdoctoral studies, until the patent registration was submitted and approved, in May this year, by the Brazilian Patent Office (BPTO).

“It was the realization of a dream, which I would not have realized without the contribution of numerous researchers from Butantan who helped me along this path”, says Halyka, who is now a university professor and directs two laboratories in Nova Friburgo (RJ). Besides her, Wilmar and Roxane, scientists Karina Scaramuzzi, Ivan Pereira Nascimento, Jorge da Costa Ferreira Junior, Cecilia Abe, and Andre Kipnis are also listed as inventors of the patent, due to their technical contribution. “We do not work interested in personal profit, but in the good that a vaccine will bring to society”, emphasizes Professor Wilmar.

The next stage of the research will be the realization of pre-clinical and clinical trials (phases 1, 2, and 3). “We still have a long way to go, but the approval of the patent will certainly facilitate the negotiation of this new technology”, celebrates the innovation manager at Butantan, Cristiano Gonçalves Pereira.

Source: Pfarma